somatostatin
Recombinant proteinexperimental
Somatostatin, also known as growth hormone-inhibiting hormone (GHIH) or by several other names, is a peptide hormone that regulates the endocrine system and affects neurotransmission and cell proliferation via interaction with G protein-coupled somatostatin receptors and inhibition of the release of numerous secondary hormones. Somatostatin inhibits insulin and glucagon secretion. — Wikipedia
Clinical trial activity
48 trials · 78 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
14
Phase 3
12
Phase 4
12
Earliest trial started Jul 1, 1999 (NCT00431665)
Timeline
Indications
Approved for
Studied for
- Carcinoid Tumor · Phase 2
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Islet Cell · Phase 2
- Diabetic Retinopathy · Phase 2/Phase 3
- Dwarfism, Pituitary · Phase 1
- End Stage Liver Disease · Phase 4
- Esophageal and Gastric Varices · Phase 4
- Gallbladder Neoplasms · Phase 3
- General Surgery · Phase 3
- Growth and Development · Phase 2
- Healthy Volunteers · Phase 4
- Hemorrhage · Phase 4
- Hypertension, Portal · Phase 4
- Hypoglycemia · Phase 1
- Infant, Small for Gestational Age · Phase 2
- Intestinal Diseases · Phase 4
- Intestinal Neoplasms · Phase 4
- Liver Cirrhosis · Phase 4
- Liver Failure · Phase 3
- Neoplasms · Phase 2/Phase 3
- Neuroendocrine Tumors · Phase 2/Phase 3
- Obesity · Early Phase 1
- Pancreatic Diseases · Phase 2/Phase 3
- Pancreatic Fistula · Phase 4
- Pancreatic Neoplasms · Phase 4
- Pancreatitis · Phase 3
- Pancreatitis, Acute Necrotizing · Phase 4
- Peptic Ulcer · Phase 2
- Polycystic Kidney, Autosomal Dominant · Phase 3
- Prostatic Neoplasms · Phase 1
- Stomach Neoplasms · Phase 4
- Turner Syndrome · Phase 2
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O- Mol. weight
- 1637.91 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSomatostatin ↗
- ChEMBLCHEMBL1823872 ↗
Also known as
- aminopan
- growth hormone release-inhibiting factor
- somatostatin
- somatostatin
- somatostatin
- somatostatin
- somatostatin
- somatostatin
- somatostatin
- somatostatin
- somatostatin
- somatotropin release-inhibiting hormone
- srif-14
- srif-14
- srif-14
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07304466 | N/A | Dec 29, 2025 | Istanbul Medipol University |
| NCT07252401 | N/A | Dec 25, 2025 | People's Liberation Army of China |
| NCT06416969 | Early Phase 1 (Phase 1) | Oct 1, 2024 | Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT06855095 | Phase 2/Phase 3 (Phase 3) | Jun 25, 2024 | Netherlands Cancer Institute |
| NCT06135168 | Phase 1 | Dec 10, 2023 | GeneScience Pharmaceuticals Co., Ltd. |
| NCT06135155 | Phase 1 | Nov 24, 2023 | GeneScience Pharmaceuticals Co., Ltd. |
| NCT05701241 | Phase 4 | Jun 28, 2023 | Erasmus University Rotterdam, Katholieke Universiteit Leuven, University of Antwerp, ZonMw: The Netherlands Organisation for Health Research and Development |
| NCT05838885 | Phase 2 | Feb 15, 2022 | Huazhong University of Science and Technology, Xiamen Amoytop Biotech Co., Ltd. |
| NCT03998293 | Phase 4 | Jun 1, 2020 | Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT04107428 | Phase 4 | Dec 31, 2019 | CEINGE - Biotecnologie Avanzate, Napoli, Italia, King Faisal University, University of Naples Frederico II |
| NCT03998709 | Phase 4 | Oct 1, 2019 | Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT04010669 | Phase 3 | Aug 1, 2019 | University of Athens |
| NCT04329039 | Phase 2/Phase 3 (Phase 3) | Jul 16, 2019 | Mayo Clinic |
| NCT04358016 | Phase 4 | Jan 1, 2018 | Changhai Hospital, Jiao Tong University |
| NCT03349424 | Phase 4 | Dec 31, 2017 | Chinese Academy of Medical Sciences |
| NCT03241706 | Phase 1 | Sep 1, 2017 | University of Cincinnati |
| NCT02705651 | Phase 3 | Jun 1, 2017 | University of Vienna |
| NCT03000946 | Phase 3 | Feb 1, 2017 | University of Paris |
| NCT02836353 | N/A | Jan 1, 2017 | University of Cambridge |
| NCT02799212 | Phase 3 | Jan 1, 2017 | University of Lyon |
Showing 20 of 48 trials
Page 1 / 3
Organizations
Research & Development (78)
78 organizations
Page 1 / 4